[1] Q Y, T C, Z Y, et al. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma[J]. World journal of surgical oncology, 2020, 18(1): 24.
[2] Tan P, Xie N, Ai J, et al. The prognostic significance of Albumin-to-Alkaline Phosphatase Ratio in upper tract urothelial carcinoma[J]. Scientific reports, 2018, 8(1): 12311.
[3] M L, P Y, G M, et al. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis[J]. International journal of surgery (London, England), 2019, 72: 206-213.
[4] S X, Y G, Y Y, et al. The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis[J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, 127: 110141.
[5] Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability[J]. Carcinogenesis, 2009, 30(7): 1073-81.
[6] Alberto, Mantovani, Paola, et al. Cancer-related inflammation[J]. Nature, 2008.
[7] Hirahara T, Arigami T, Yanagita S, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer[J]. BMC cancer, 2019, 19(1): 672.
[8] Suzuki S, Akiyoshi T, Oba K, et al. Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer[J]. Annals of surgical oncology, 2020, 27(3): 844-852.
[9] Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer[J]. Annals of surgery, 2020, 272(2): 342-351.
[10] Pointer D, Roife D, Powers B, et al. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma[J]. BMC cancer, 2020, 20(1): 750.
[11] Tian G, Li G, Guan L, et al. Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid cancers: A meta-analysis with trial sequential analysis[J]. International journal of surgery (London, England), 2020, 81: 66-73.
[12] Lh L, C Z, W W, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study[J]. Liver international : official journal of the International Association for the Study of the Liver, 2020.
[13] Okugawa Y, Toiyama Y, Fujikawa H, et al. Prognostic Potential of Lymphocyte-C-Reactive Protein Ratio in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy[J]. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020.
[14] He H, Guo W, Song P, et al. Preoperative systemic immune-inflammation index and prognostic nutritional index predict prognosis of patients with pulmonary neuroendocrine tumors after surgical resection[J]. Annals of translational medicine, 2020, 8(10): 630.
[15] Wang Y, Zhu Z, Li C, et al. Prognostic significance of preoperative albumin-to-globulin ratio and prognostic nutritional index combined score in Siewert type 3 adenocarcinoma of esophagogastric junction[J]. Cancer management and research, 2019, 11: 7631-7638.
[16] Carr B, Guerra V. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients[J]. The International journal of biological markers, 2017, 32(4): e391-e396.
[17] Ikeda S, Yoshioka H, Ikeo S, et al. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status[J]. BMC cancer, 2017, 17(1): 797.
[18] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation[J]. The New England journal of medicine, 1999, 340(6): 448-54.
[19] Ilhan N, Ilhan N, Ilhan Y, et al. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer[J]. World journal of gastroenterology, 2004, 10(8): 1115-20.
[20] Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland[J]. The Journal of clinical investigation, 2007, 117(12): 3988-4002.
[21] De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer[J]. Clinical breast cancer, 2012, 12(4): 264-9.
[22] Ownby H, Roi L, Isenberg R, et al. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer[J]. Cancer, 1983, 52(1): 126-30.
[23] Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer management and research, 2017, 9: 849-867.
[24] Mcmillan D C, Watson W S, O'gorman P, et al. Albumin Concentrations Are Primarily Determined by the Body Cell Mass and the Systemic Inflammatory Response in Cancer Patients With Weight Loss[J]. Nutrition & Cancer, 2001.
[25] Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis[J]. Journal of hepatology, 2014, 61(2): 396-407.
[26] Rader B A. Alkaline Phosphatase, an Unconventional Immune Protein[J]. Frontiers in Immunology, 2017, 8.
[27] Warnes T. Progress report—alkaline phosphatase[J]. Gut, 1972, 13: 937-962.
[28] Yu M C, Chan K M, Lee C F, et al. Alkaline Phosphatase: Does it have a Role in Predicting Hepatocellular Carcinoma Recurrence?[J]. Journal of Gastrointestinal Surgery Official Journal of the Society for Surgery of the Alimentary Tract, 2011, 15(8): 1440.
[29] Ning P, Shanshan G, Yadong X, et al. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection[J]. Journal of Cancer, 2017, 8(16): 3362-3370.
[30] Tiainen S, Rilla K, Hämäläinen K, et al. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype[J]. Breast cancer research and treatment, 2020.
[31] Li X, Yao Z, Wan Y, et al. Prognostic impact of prognostic nutritional index in advanced (stage IIIB/IV) non-small cell lung cancer patients[J]. Neoplasma, 2019, 66(6): 971-977.
[32] X H, H H, W Z, et al. Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma[J]. Journal of cellular physiology, 2019, 234(10): 18408-18414.
[33] Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer[J]. Clinical nutrition (Edinburgh, Scotland), 2020, 39(4): 1209-1217.
[34] Li S, Lu S, Liu X, et al. Association Between the Pretreatment Albumin-to-Alkaline Phosphatase Ratio and Clinical Outcomes in Patients With Bladder Cancer Treated With Radical Cystectomy: A Retrospective Cohort Study[J]. Frontiers in oncology, 2021, 11: 664392.
[35] Yj L, K Y, Mx L, et al. Prognostic value of the C-reactive protein to albumin ratio: a novel inflammation-based prognostic indicator in osteosarcoma[J]. OncoTargets and therapy, 2017, 10: 5255-5261.
[36] B L, Y H, Y S, et al. Prognostic value of inflammation-based scores in patients with osteosarcoma[J]. Scientific reports, 2016, 6: 39862.
[37] T L, Xc F, Z D, et al. Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma[J]. FEBS open bio, 2015, 5: 682-7.
[38] Hu H, Deng X, Song Q, et al. Prognostic Value of the Preoperative Lymphocyte-to-C-Reactive Protein Ratio and Albumin-to-Globulin Ratio in Patients with Osteosarcoma[J]. OncoTargets and therapy, 2020, 13: 12673-12681.